Smith & Nephew plc ADR Stock
Pros and Cons of Smith & Nephew plc ADR in the next few years
Pros
?
C******** o* t** e**********
?
W********* I********* f** t** n*** y****
?
M***** P*******
Cons
?
S********** s********
?
B****
?
G***** c******* t* c**********
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Smith & Nephew plc ADR vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Smith & Nephew plc ADR | - | -2.721% | 2.143% | 17.213% | 2.143% | 10.000% | -19.209% |
| Smith & Nephew plc | -1.860% | -3.258% | 1.135% | 14.775% | 0.281% | 10.077% | -19.690% |
| Dexcom Inc. | -1.930% | 3.540% | 6.671% | -26.967% | 4.606% | -39.349% | -18.227% |
| Thermo Fisher Scientific Inc. | -2.340% | 0.301% | 11.213% | -2.020% | 7.972% | -0.763% | 26.221% |
Comments
Smith & Nephew SNATS (NYSE:SNN) was upgraded by analysts at Wall Street Zen from a "buy" rating to a "strong-buy" rating.
Show more
Ratings data for SNN provided by MarketBeat
Smith & Nephew SNATS (NYSE:SNN) had its "outperform" rating reaffirmed by analysts at Royal Bank Of Canada.
Show more
Ratings data for SNN provided by MarketBeat
Smith & Nephew plc (NYSE: SNN) is now covered by analysts at Deutsche Bank Aktiengesellschaft. They set a "buy" rating on the stock.
Show more
Ratings data for SNN provided by MarketBeat
